Systematic review: the epidemiology and natural history of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis in adults

By G. Vernon, A. Baranova, Z. Younossi. Alimentary Pharmacology and Therapeutics, 2011

3,067 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Epidemiology, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/14c238aac9fbd8f0ab62bb82333d05ee345bbb87

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

1. Z. Younossi
2. M. Rinella
3. R. Loomba
4. Q. Anstee
5. K. Cusi
6. Asociacion Latinoamericana para el Estudio del Higado
7. A. Sanyal
8. Bart Staels

In Epidemiology

1. Z. Younossi
2. M. Rinella
3. A. Sanyal
4. K. Cusi
5. R. Loomba
6. Q. Anstee
7. E. Brunt
8. J. Lavine

In Pathology and Forensic Medicine

1. Z. Younossi
2. Q. Anstee
3. A. Sanyal
4. M. Rinella
5. K. Cusi
6. E. Brunt
7. Asociacion Latinoamericana para el Estudio del Higado
8. R. Loomba

Citations in the corpus

• Non-alcoholic fatty liver disease - A global public health perspective. (2019, background): “In addition to these liver diseases, it is important to mention that NAFLD also encompasses patients with cryptogenic cirrhosis.(5,15,16) Although controversial, recent biopsy data suggested that patients with cryptogenic cirrhosis are a part of the spectrum of NASH but may experience worse outcomes”
• Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: A connection between endogenous alcohol and NASH (2013, background): “(HEPATOLOGY 2013;57:601-609) N onalcoholic fatty liver disease (NAFLD), the hepatic manifestation of metabolic syndrome, is the most common cause of elevated liver enzymes in the United States.1 NAFLD with inflammation and fibrosis is known as nonalcoholic steatohepatitis (NASH) because it resembles”
• Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening. (2016, background): “These 2 latter conditions carry the heaviest toll in terms of mortality, the leading cause of death being from cardiovascular events.(3,7,8) Peroxisome proliferator activated receptors (PPARs) are nuclear receptors playing key roles in cellular processes regulating metabolic homeostasis, immune-infl”
• Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomes (2016, background): “Clinically, NAFLD patients tend to be obese, with insulin resistance and/or type 2 diabetes, dyslipidemia, hypertriglyceridemia, and hypertension, which are all risk factors for cardiovascular diseases (CVDs).((10,11)) In fact, prevalence of NAFLD in patients with components of MetS is quite high.”
• Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease (2017, background): “Reported estimates state that 3-5% of adults in the US have NASH (4, 16, 19, 20).”
• Gut microbiome based metagenomic signature for non-invasive detection of advanced fibrosis in human nonalcoholic fatty liver disease (2017, neutral): “(Loomba and Sanyal, 2013; Rinella, 2015; Vernon et al., 2011) NAFLD is broadly sub-divided into two phenotypes: nonalcoholic fatty liver (NAFL), which is considered the non-progressive subtype, and nonalcoholic steatohepatitis (NASH), which is considered the progressive subtype that can lead to cirr”